Vaccitech rises on promising interim data from hepatitis B study

Barinthus Biotherapeutics

22/06/2022 17:24

** Shares of biopharmaceutical company Vaccitech plc
 VACC.O  rise 3.5% to $4.71
    ** Co says new interim data from ongoing study of
experimental therapy, VTP-300, in chronic hepatitis B patients
shows that it produces meaningful, durable reductions of surface
antigen HBsAg in some patients  urn:newsml:reuters.com:*:nFWN2Y80Z8
    ** HBsAg is the surface antigen of the hepatitis B virus;
its presence in blood indicates current hepatitis B infection
    ** Enrollment in study is complete with 55 patients
enrolled; updated interim analysis for all patients at six-month
follow-up timepoint is expected end of 2022
    ** Including session moves, stock down ~57.52% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))